Northwire Canada EditionSaturday, October 17, 2026
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Other

Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook

MDNA · Price

Executive Summary

  • MDNA11 demonstrated ORR of 50% (2L/3L) and 42% (post‑ICI) in monotherapy expansion cohorts, indicating best‑in‑class potential.
  • MDNA113 showed a favorable safety profile in non‑human primates at 30 mg/kg, supporting progression to first‑in‑human trials in H2 2026.
  • Updated cash guidance extends runway into Q3 2026; the company outlined multiple 2026 milestones including completion of ABILITY‑1 enrollment, IND filing for MDNA113, and partnership/financing activities for bizaxofusp.

Key Details

  • MDNA11 Clinical Data (ABILITY‑1):
  • Monotherapy expansion (n=21) – ORR 50% (2L/3L), 42% (post‑ICI).
  • All efficacy‑evaluable monotherapy patients (n=55, 18 cancers) – ORR 19% (2L/3L), 24% (post‑ICI).
  • Combination with pembrolizumab: 50% ORR in MSS endometrial cancer (n=4); 43% ORR in MSS TMB‑H cancers (n=7); 25% ORR in MSI‑H cancers (n=4); 17% ORR in cutaneous melanoma (n=6).
  • Sub‑group results: 37.5% ORR in cutaneous melanoma (2° ICI resistance, n=8); 25% ORR in MSI‑H cancers (n=8).

  • NEO‑CYT Trial:

  • Randomized neoadjuvant study of MDNA11 + nivolumab ± ipilimumab in high‑risk resectable Stage III melanoma.
  • Enrollment planned H1 2026; interim readout H2 2026.

  • MDNA113 Pre‑clinical Data:

  • Well tolerated in non‑human primates up to 30 mg/kg, no C‑reactive protein increase, limited peripheral T‑cell expansion despite high dose.
  • Supports human dosing comparable to standard anti‑PD‑1 therapies.
  • IND filing expected H2 2026; Phase 1/2a trial targeted for Q4 2026.

  • Bizaxofusp Development:

  • Ongoing partnering discussions; data to be presented at 7th Annual Glioblastoma Development Summit (Boston, 17‑19 Feb 2026).

  • Financial Outlook:

  • Updated cash guidance provides runway into Q3 2026.
  • Intent to strengthen balance sheet via partnership or financing by mid‑2026.

  • 2026 Strategic Milestones:

  • Complete ABILITY‑1 enrollment across prioritized indications (melanoma, endometrial, MSI‑H/dMMR, MSS/TMB‑H).
  • Report updated MDNA11 clinical data and interim NEO‑CYT results.
  • Secure FDA guidance for potential registrational trial of MDNA11 in a 2L/3L indication.
  • File IND for MDNA113 (H2 2026) and initiate first‑in‑human trial.
  • Advance bizaxofusp partnership/collaboration and present new pre‑clinical data Q1 2026.

Notable Quotes

  • “We are encouraged by the updated and expanding clinical data set for MDNA11… which has unquestionably positioned it as a best‑in‑class IL‑2 super agonist.” – Fahar Merchant, PhD, President & CEO, Medicenna Therapeutics.
Read the original news release →

More from MEDICENNA THERAPEUTICS CORP. J